Effects of Ulinastatin on Myocardial Protection and Blood Loss in Patients Undergoing Aortic Valve Replacement
NCT ID: NCT00944385
Last Updated: 2011-05-27
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
INTERVENTIONAL
2009-06-30
2011-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Effects of Statin on Postoperative Renal Function in Valvular Heart Surgery: a Randomized, Placebo-controlled Study
NCT01909739
Protective Effect in Cardiac Surgery Patients
NCT04028024
The Effect of Atorvastatin on Prevention of Postoperative Acute Kidney Injury in Patients Undergoing Aortic Surgery
NCT02157337
Effects of High Dose Atorvastatin in Patients With Surgical Aortic Stenosis
NCT00811330
Preoperative Statin Use and Major Adverse Cardiovascular Events in Liver Transplant Recipients
NCT07089589
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
ulinastatin
Administer with 30,000U /ulinastatin
ulinastatin
Administer 30000U/ulinastatin. Comparison of different dosages of drug.
C group
administer normal saline
ulinastatin
Administer 30000U/ulinastatin. Comparison of different dosages of drug.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
ulinastatin
Administer 30000U/ulinastatin. Comparison of different dosages of drug.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* tricuspid valve failure from moderate to severe
* urgent surgery required
* infectious endocarditis
20 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Yonsei University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Severance Hospital
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Younglan Kwak, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Severance Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Severance Hospital
Seoul, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
4-2009-0079
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.